SCHEMBL6947718

SCHEMBL6947718

CCCCN1CCC(=O)CC1.CCCCNCCCC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
THRB P10828 1/20 0.39
HPGD P15428 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
DRD2 P14416 1/20 0.38
CHRM3 P20309 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
TSHR P16473 2/20 0.37
CYP1A2 P05177 1/20 0.36
PAOX Q6QHF9 1/20 0.36
USP2 O75604 1/20 0.36
HRH3 Q9Y5N1 1/20 0.35
GNAI3 P08754 1/20 0.35
GNAO1 P09471 1/20 0.35
GNAI1 P63096 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6945104 0.95 GNAI3 (0.41) ALDH1A1TSHRGNAI3GNAO1GNAI1
SCHEMBL6947485 0.93 POLB (0.38) ALDH1A1THRBL3MBTL1TSHRCYP1A2
SCHEMBL6948499 0.93 ALDH1A1 (0.39) ALDH1A1THRBHPGDL3MBTL1CHRM2
SCHEMBL7246872 0.93 ACE2 (0.42) ALDH1A1THRBHPGDL3MBTL1TSHR
SCHEMBL8108347 0.89 ALDH1A1 (0.45) ALDH1A1THRBHPGDL3MBTL1CHRM2
SCHEMBL3728839 0.89 ALDH1A1 (0.45) ALDH1A1THRBHPGDL3MBTL1CHRM2
SCHEMBL6942247 0.88 GNAI3 (0.41) GNAI3GNAO1GNAI1
SCHEMBL6943645 0.87 ALDH1A1 (0.40) ALDH1A1THRBHPGDL3MBTL1TSHR
Diethylamine SCHEMBL6944033 0.87 ALDH1A1 (0.40) ALDH1A1THRBHPGDL3MBTL1CHRM2
Dimethylamine SCHEMBL8109560 0.87 ALDH1A1 (0.42) ALDH1A1THRBHPGDL3MBTL1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 ALDH1A1 2147/4885THRB 4377/4885HPGD 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.